These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 24442754

  • 1. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
    Yokota T.
    Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754
    [Abstract] [Full Text] [Related]

  • 2. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG.
    PLoS One; 2013 Apr; 8(2):e56112. PubMed ID: 23405260
    [Abstract] [Full Text] [Related]

  • 3. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S, Chrétien AS, Ramacci C, Rouyer M, Becuwe P, Merlin JL.
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [Abstract] [Full Text] [Related]

  • 4. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
    Kondo N, Tsukuda M, Taguchi T, Nakazaki K, Sakakibara A, Takahashi H, Toth G, Nishimura G.
    Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
    [Abstract] [Full Text] [Related]

  • 5. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P, Gonzalez S.
    Pathol Res Pract; 2011 Jun 15; 207(6):337-42. PubMed ID: 21531084
    [Abstract] [Full Text] [Related]

  • 6. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.
    Acta Oncol; 2014 Jul 15; 53(7):852-64. PubMed ID: 24666267
    [Abstract] [Full Text] [Related]

  • 7. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
    Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, Baldus SE, Schaefer KL.
    J Cancer Res Clin Oncol; 2013 Feb 15; 139(2):201-9. PubMed ID: 23015072
    [Abstract] [Full Text] [Related]

  • 8. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A, Peyrade F, Milano G.
    Anticancer Agents Med Chem; 2013 Mar 15; 13(3):389-402. PubMed ID: 23092267
    [Abstract] [Full Text] [Related]

  • 9. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
    Pogorzelski M, Ting S, Gauler TC, Breitenbuecher F, Vossebein I, Hoffarth S, Markowetz J, Lang S, Bergmann C, Brandau S, Jawad JA, Schmid KW, Schuler M, Kasper S.
    Cell Death Dis; 2014 Feb 27; 5(2):e1091. PubMed ID: 24577089
    [Abstract] [Full Text] [Related]

  • 10. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
    Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind JS.
    J Natl Cancer Inst; 2014 Sep 27; 106(9):. PubMed ID: 25099740
    [Abstract] [Full Text] [Related]

  • 11. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
    Leblanc O, Vacher S, Lecerf C, Jeannot E, Klijanienko J, Berger F, Hoffmann C, Calugaru V, Badois N, Chilles A, Lesnik M, Krhili S, Bieche I, Le Tourneau C, Kamal M.
    Cancer Biol Med; 2020 Feb 15; 17(1):208-217. PubMed ID: 32296588
    [Abstract] [Full Text] [Related]

  • 12. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
    Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, Kako SL, Takimoto SM, Sehrt DB, Umpierrez A, Pittman MA, Macfadden SM, Helber RM, Peterson S, Hausman DF, Said S, Leem TH, Goddard JA, Arcaroli JJ, Messersmith WA, Robinson WA, Hirsch FR, Varella-Garcia M, Raben D, Wang XJ, Song JI, Tan AC, Jimeno A.
    Mol Oncol; 2013 Aug 15; 7(4):776-90. PubMed ID: 23607916
    [Abstract] [Full Text] [Related]

  • 13. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Bardelli A, Siena S.
    J Clin Oncol; 2010 Mar 01; 28(7):1254-61. PubMed ID: 20100961
    [Abstract] [Full Text] [Related]

  • 14. Human papillomavirus and gene mutations in head and neck squamous carcinomas.
    Friedland P, Thomas A, Naran A, Amanuel B, Grieu-Iacopetta F, Carrello A, Harnett G, Meyer C, Phillips M.
    ANZ J Surg; 2012 May 01; 82(5):362-6. PubMed ID: 22507644
    [Abstract] [Full Text] [Related]

  • 15. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
    Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, Makatsoris T, Papakostas P, Bai M, Goussia A, Samantas E, Papamichael D, Romanidou O, Efstratiou I, Tsolaki E, Psyrri A, De Roock W, Bafaloukos D, Klouvas G, Tejpar S, Kalogeras KT, Pectasides D, Fountzilas G.
    J Cancer Res Clin Oncol; 2014 May 01; 140(5):737-48. PubMed ID: 24595598
    [Abstract] [Full Text] [Related]

  • 16. A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.
    Bahassi el M, Li YQ, Wise-Draper TM, Deng L, Wang J, Darnell CN, Wilson KM, Wells SI, Stambrook PJ, Rixe O.
    Eur J Cancer; 2013 Jul 01; 49(10):2345-55. PubMed ID: 23578570
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
    Smilek P, Neuwirthova J, Jarkovsky J, Dusek L, Rottenberg J, Kostrica R, Srovnal J, Hajduch M, Drabek J, Klozar J.
    Neoplasma; 2012 Jul 01; 59(5):508-15. PubMed ID: 22668015
    [Abstract] [Full Text] [Related]

  • 18. Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.
    Silvestris N, Vincenzi B, Brunetti AE, Loupakis F, Dell'Aquila E, Russo A, Scartozzi M, Giampieri R, Cascinu S, Lorusso V, Tonini G, Falcone A, Santini D.
    Pharmacogenomics; 2014 Sep 01; 15(13):1701-15. PubMed ID: 25410895
    [Abstract] [Full Text] [Related]

  • 19. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
    Zaryouh H, De Pauw I, Baysal H, Peeters M, Vermorken JB, Lardon F, Wouters A.
    Med Res Rev; 2022 Jan 01; 42(1):112-155. PubMed ID: 33928670
    [Abstract] [Full Text] [Related]

  • 20. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.
    J Clin Oncol; 2009 Dec 10; 27(35):5924-30. PubMed ID: 19884556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.